$1.55 Billion is the total value of Camber Capital Management LP's 45 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 59.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTDadr | $118,152,000 | +4.6% | 1,800,000 | -10.0% | 7.64% | -21.1% |
| MDCO | Sell | MEDICINES CO | $82,148,000 | -13.4% | 2,200,000 | -12.0% | 5.31% | -34.7% |
| AZN | Sell | ASTRAZENECA PLCsponsored adr | $67,900,000 | -14.6% | 2,000,000 | -20.0% | 4.39% | -35.6% |
| MYL | Sell | MYLAN N V | $67,588,000 | +11.9% | 1,250,000 | -16.7% | 4.37% | -15.6% |
| MJN | Sell | MEAD JOHNSON NUTRITION CO | $39,475,000 | -6.5% | 500,000 | -16.7% | 2.55% | -29.5% |
| LH | Sell | LABORATORY CORP AMER HLDGS | $37,092,000 | -14.5% | 300,000 | -25.0% | 2.40% | -35.5% |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC COM | $33,783,000 | +4.5% | 5,405,235 | -2.3% | 2.18% | -21.1% |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $5,037,000 | -11.6% | 649,097 | -10.4% | 0.32% | -33.4% |
| ANGO | Sell | ANGIODYNAMICS INC | $2,952,000 | -13.3% | 243,183 | -5.8% | 0.19% | -34.6% |
| AZN | Exit | BIOLASE INCcall | $0 | – | -1,841,173 | -100.0% | 0.00% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -192,935 | -100.0% | -0.08% | – |
| VCYT | Exit | VERACYTE INC | $0 | – | -910,334 | -100.0% | -0.37% | – |
| PODD | Exit | INSULET CORP | $0 | – | -245,000 | -100.0% | -0.54% | – |
| ABT | Exit | ABBOTT LABS | $0 | – | -300,000 | -100.0% | -1.03% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -6,500,000 | -100.0% | -1.08% | – |
| KND | Exit | KINDRED HEALTHCARE INC | $0 | – | -1,100,000 | -100.0% | -1.48% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -9,750,000 | -100.0% | -1.60% | – |
| HMSY | Exit | HMS HLDGS CORP | $0 | – | -2,179,900 | -100.0% | -1.64% | – |
| ALNY | Exit | ALYNYLAM PHARMACEUTICALS INC | $0 | – | -250,000 | -100.0% | -1.72% | – |
| CCRN | Exit | CROSS CTRY HEALTHCARE INC | $0 | – | -1,493,765 | -100.0% | -1.74% | – |
| ESRX | Exit | EXPRESS SCRIPTS HLDG CO | $0 | – | -600,000 | -100.0% | -4.16% | – |
| CYBX | Exit | CYBERONICS INC | $0 | – | -1,000,000 | -100.0% | -5.21% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.